Regimen confers ‘meaningful’ benefit in aggressive lymphoma, may become a new standard

medpagetoday.com·May 30, 2026 · 1 mesi fa

Frontline Targeted Therapies Plus R-CHOP Boosts PFS in High-Risk B-Cell Lymphomas

morningstar.com·May 30, 2026 · 1 mesi fa

Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL

ecodibergamo.it·May 30, 2026 · 1 mesi fa

frontMIND, lo studio clinico cardine di Incyte ha dimostrato come la combinazione tafasitamab (Monjuvi®/Minjuvi®) sia in grado di prolungare notevolmente la sopravvivenza libera da progressione, riducendo il rischio di progressione della malattia...

medpagetoday.com·Jun 1, 2026 · 1 mesi fa

CELMoD Drug Cuts Risk of Myeloma Progression, Death by 52% in Trial

medpagetoday.com·Jun 2, 2026 · 1 mesi fa

Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer

fiercepharma.com·May 30, 2026 · 1 mesi fa

ASCO: With bispecifics on its heels, Incyte positions Monjuvi combo for first-line DLBCL

morningstar.com·May 31, 2026 · 1 mesi fa

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) pivotal data show strong and durable responses in advanced head and neck cancer where options remain limited

medpagetoday.com·May 30, 2026 · 1 mesi fa

Drug Combo for Lung Cancer Beats Pembrolizumab in First-Line Trial

morningstar.com·May 29, 2026 · 1 mesi fa

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer

medpagetoday.com·May 31, 2026 · 1 mesi fa

Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma